(Q43921035)

English

A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma

scientific article published in January 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Giuseppe Procopio

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Antonia Martinetti

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

author name string

Emilio Bajetta

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Leonardo Ferrari

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Nicoletta Zilembo

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Laura Catena

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Massimiliano Alú

7

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Torre Silvia Della

8

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Daniele Alberti

9

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Roberto Buzzoni

10

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

language of work or name

0 references

publication date

1 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

94

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

299-304

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

Growth regulation of human breast carcinoma occurs through regulated growth factor secretion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

Mechanisms of antineoplastic action of somatostatin analogs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

Some practical aspects of the interim monitoring of clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

Interim monitoring of clinical trials based on long-term binary endpoints

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

Insulin-like growth factors and cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

Biological and clinical evaluation of Lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

Octreotide as first-line treatment for women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

Preclinical studies on the anticancer activity of the somatostatin analogue octreotide (SMS 201-995)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

21 January 2018

Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10239

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.10239

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43921035&oldid=2104404674"